A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Key Inclusion Criteria: * Documented evidence of acquired hypothalamic obesity (HO) * Age 12 years and older * Weight gain associated with the hypothalamic injury and a BMI of ≥30 kg/m2 for patients ≥18 years of age or BMI ≥95th percentile for age and sex for patients \<18 years of age * Male and female participants agree to follow study contraception requirements and use a highly effective form of contraception throughout the study and for 90 days after the study Key Exclusion Criteria: * Weight loss \>2% in the previous 3 months for patients ≥18 years of age or \>2% reduction in BMI for patients \<18 years of age * History of major surgical procedure within 30 days * HbA1c \>10.9% * Fasting glucose level \>270 mg/dL * Previous use of MC4R agonists * Diagnosis of Prader-Willi syndrome (PWS) or Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumor syndrome (ROHHADNET). * Diagnosis of severe psychiatric disorders; any suicidal ideation, attempt or behavior * History or close family history of skin cancer or melanoma * Current clinically significant pulmonary, cardiac, or oncologic disease considered severe enough to interfere with the study and/or confound the results Other protocol defined Inclusion/Exclusion criteria may apply.